A Phase 4 clinical trial referencing GLP-1 receptor agonists, including liraglutide, reached completed status as of September 2, 2026. The study, registered as NCT06981936, was titled "This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control."
The trial was designed to compare balanced nutritional tablets, described as comprehensive multivitamin and mineral supplements, against a placebo control. The stated purpose was to investigate whether such supplements could help prevent micronutrient deficiencies in patients using GLP-1 receptor agonists for weight loss.
This trial update reflects only the completion status recorded in the registry entry. No results, outcomes, or efficacy data are included in this update, and none should be inferred from the completed status alone. The registry listing does not specify whether results have been posted publicly.
Readers interested in liraglutide's approved uses and regulatory background can consult the compound overview for additional context.